Clinical trials: Platinum-Sensitive Primary Peritoneal Carcinoma
Chemotherapy-induced Peripheral Neuropathy, Recurrent Ovarian Carcinoma
High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy
This study aims to evaluate the safety and efficacy of high dose inorganic selenium in preventing and relieving chemotherapy-induced peripheral neuropathy (CIPN) in platinum-sensitive recurrent ovarian, fallopian, or primary…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Recurrent Ovarian Carcinoma, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- SELENIUM (NCT04201561)
- Testing
- sodium selenite pentahydrate, Normal saline, Chemotherapy
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Platinum-sensitive Relapsed Ovarian Cancer
Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
This is a 2:1 randomized, double-blind, placebo-controlled, multi-center, phase III clinical study evaluating the efficacy and safety of ZL-2306 (niraparib) for maintenance treatment in patients with platinum-sensitive relapsed…
- Trial name
- NCT03705156
- Testing
- ZL-2306(nirapairb)
- Where
- 27 sites in China
- Volunteers
- 265 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or…
- Trial name
- NCT02983799
- Testing
- OLAPARIB
- Where
- 47 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent…
- Conditions
- High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- UP-NEXT (NCT05329545)
- Testing
- Upifitimab rilsodotin
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- Mersana Therapeutics
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation and peripheral stem cell transplantation may allow doctors to give higher doses…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002600
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer, Peritoneal Cavity Cancer
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00217568
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
This phase I/II trial studies the side effects and best dose of olaparib when give together with durvalumab and tremelimumab and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal…
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02953457
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Carcinoma, Fallopian Tube Carcinoma
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT06420973
- Testing
- RC48+carboplatin±bevacizumab
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT02446600
- Testing
- Biospecimen Collection, Carboplatin, Cediranib Maleate
- Where
- 356 sites in United States, Canada and 2 more
- Volunteers
- 579 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020696
- Testing
- cisplatin, tirapazamine
- Where
- 54 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group
Ovarian Neoplasms, Peritoneal Neoplasms
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01846611
- Testing
- Trabectedin, DOXIL, Dexamethasone
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 581 people
- Sponsor
- Janssen Research & Development, LLC
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00096200
- Testing
- Carboplatin, Paclitaxel, Sorafenib Tosylate
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
purpose Primary endpoint To evaluate the 24 month disease free survival Second endpoints To evaluate the 24 month overall survival To analyze the toxicity and the quality of life
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01570582
- Testing
- carboplatin and paclitaxel
- Where
- South Korea
- Volunteers
- 314 people
- Sponsor
- Korean Gynecologic Oncology Group
High Grade Ovarian Cancer, Primary Peritoneal Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade…
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05456685
- Testing
- Mirvetuximab soravtansine, Carboplatin
- Where
- 69 sites in United States, Belgium and 4 more
- Volunteers
- 125 people
- Sponsor
- AbbVie
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)